Open Access

Poster session 1 - Posters Group 1

Event: EuroPRevent Meeting 2016
Topic: Miscellaneous
Session type: Poster Session
Date: 14 June 2016

Session

8 presentations in this session

Poster discussant Group1:

Thumbnail

Atrial fibrillation as risk of lethal death after PCI

Speaker: Professor O. Londono Sanchez (Barcelona, ES)
Thumbnail

Are we diagnosing and properly treating atrial fibrillation in the elderly?

Speaker: Assistant Professor P. Monteiro (Coimbra, PT)
Thumbnail

The prevalence of cognitive impairment and silent brain infarctions at different forms of atrial fibrillation

Speaker: Professor G. Chumakova (Barnaul, RU)
Thumbnail

The stroke prevention in patients with atrial fibrillation in Kazakhstan

Speaker: Mrs D. Akpanova (Almaty, KZ)
Thumbnail

Does a unique clinical pathway for atrial fibrillation (af) plus education improve rates of anticoagulation and reduce af-related stroke?

Speaker: Doctor J. Mills (Liverpool, GB)
Thumbnail

Holt-Oram syndrome

Speaker: Doctor N. Naidoo (Durban, ZA)
Thumbnail

Prognostic value of AGTR1 and AGTR2 gene polymorphisms in the development of left ventricular hypertrophy in patients with arterial hypertension

Speaker: Associate Professor V. Bondar (Odessa, UA)
Thumbnail

7 speakers from this session

Professor Oswald Londono Sanchez

San Jordi Clinic, Barcelona (Spain)
0 follower

Assistant Professor Pedro Filipe Monteiro

University Hospitals of Coimbra, Coimbra (Portugal)
0 follower

Professor Galina Chumakova

Altay State Medical University, Barnaul (Russian Federation)
0 follower

Mrs Dinara Akpanova

Scientific Research Institute of Cardiology and Internal Diseases, Almaty (Kazakhstan)
0 follower

Doctor Joseph Mills

Liverpool Heart and Chest Hospital, Liverpool (United Kingdom of Great Britain & Northern Ireland)
0 follower

Doctor Nerissa Naidoo

University of KwaZulu Natal, Durban (South Africa)
0 follower

Associate Professor Vadym Bondar

Odessa National Medical University, Odessa (Ukraine)
0 follower

This platform is supported by

logo Novo Nordisk